The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Hyperion Therapeutics, Inc. (“Hyperion” or the “Company”) (Nasdaq: HPTX) relating to the proposed buyout of the Company by Horizon Pharma plc (“Horizon”).

Under the terms of the transaction, Hyperion shareholders are anticipated to receive $46.00 in cash for each share of Hyperion common stock held. The firm’s investigation seeks to determine, among other things, whether the Company’s Board of Directors failed to satisfy their duties to shareholders, including whether the Board adequately pursued alternatives to the acquisition and whether the Board obtained the best price possible for the Company’s shares of common stock. In particular, according to Yahoo! Finance, at least one Wall Street analyst has issued a price target for Hyperion stock at $52.00 per share.

If you currently own common stock of Hyperion and would like to learn more about the investigation being conducted by Brower Piven, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentinvestigations.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.

Brower Piven, A Professional CorporationCharles J. Piven, 410-415-66161925 Old Valley RoadStevenson, Maryland 21153hoffman@browerpiven.com

(MM) (NASDAQ:HPTX)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas (MM).
(MM) (NASDAQ:HPTX)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas (MM).